NEW YORK – Natera announced on Wednesday that it is collaborating with Kupando Therapeutics on a Phase I clinical trial for skin cancer patients in Germany. Through the agreement, Natera's blood-based ...

The clearances include one for an AI-assisted quality control software that detects six common whole-slide image artifacts.

Recent catalysts such as an FDA approval, NCCN guideline inclusion, and Japanese regulatory approval have fueled the firm's goals to expand its presence.

The clearance also includes a predetermined change control plan to lower regulatory hurdles around changes to the software's use.

The firm also offered updates on its autoimmune disease, newborn screening, and other specialty diagnostics businesses from the sidelines of the conference.

Executives disclosed new directions in neurodegenerative disease testing and low-volume sample collection for high-volume testing.

The technology supports the adoption of digital pathology and artificial intelligence in cancer diagnostics by enabling greater consistency in laboratory slide staining.

Natera's Q2 net loss was $67.0 million, or $.47 per share, compared to a net loss of $100.9 million, or $.74 per share, in Q2 of last year. On average, analysts had expected a loss of $.53 per share.

Cancer early detection firm Grail said after the close of the market Wednesday that its second-quarter revenue grew 26 percent year over year, noting that it is preparing for an expected advisory ...

The issue of developing pediatric reference intervals for common laboratory tests has been one of the organization's priorities.

The company also submitted a request for a CLIA waiver for the test, which would permit its use in decentralized testing locations.

Last week, readers were most interested in a story about a staffing shortage at labs that run liquid biopsy tests as demand for the tests skyrocket.